Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares MSCI Japan ETF (EWJ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs iShares MSCI Japan ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.81 (market cap $4.49B), while iShares MSCI Japan ETF trades at $92.18. Which is the better fit depends on your goals.
| ACAD | EWJ | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $28.06 | $96.97 |
52-Week Low | $20.06 | $71.69 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
EWJ, the iShares MSCI Japan ETF, trades at $95.27, up 2.29% on the day, with a bullish technical signal driven by moving averages. The ETF provides exposure to Japanese equities, with recent news highlighting yen volatility and strong export data. Key support is at $94, with resistance at $96. A dividend of $0.50 is scheduled for June 2026.
Outlook remains tied to Japan's economic trends and currency dynamics. Opportunities include AI-driven export growth, but risks involve yen weakness and geopolitical tensions. Investors should weigh Japan's monetary policy shifts and global market sentiment for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About iShares MSCI Japan ETF
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →
